相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
Georgina Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma
Omid Hamid et al.
EUROPEAN JOURNAL OF CANCER (2017)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter et al.
LANCET (2017)
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Jason J. Luke et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Comparative study of two PD-L1 expression assays in patients with non-small cell lung cancer (NSCLC).
Zheng Feng et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Update on primary head and neck mucosal melanoma
Fernando Lopez et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2016)
Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing
Beryl Royer-Bertrand et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2016)
Cancer Statistics, 2016
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial:
F. Stephen Hodi et al.
CANCER RESEARCH (2016)
Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab
Rika Fujii et al.
ONCOTARGET (2016)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Biology of advanced uveal melanoma and next steps for clinical therapeutics
Jason J. Luke et al.
PIGMENT CELL & MELANOMA RESEARCH (2015)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives
Kristina Buder et al.
CANCER MEDICINE (2013)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
分享论文
